Objective To compare on-treatment weight loss and rates of gastrointestinal adverse events (AEs) among adults with overweight or obesity receiving tirzepatide or semaglutide labeled for type 2 diabetes (T2D) in a clinical setting
Whilst some gastrointestinal changes are expected with GLP-1 receptor agonists, ongoing diarrhoea, constipation, or other concerning symptoms may require investigation or management strategies
Medications the intake of certain medications can cause amenorrhea (absence of menstruation)
If your insurance covers brand-name GLP-1 drugs like Wegovy or Mounjaro, platforms like Found or Ro may be more cost-effective
Over 72 weeks, tirzepatide produced notably greater weight loss across every metric the researchers measured
Implants Implantable SC implants and osmotic pumps represent advanced technologies for sustained drug delivery, leveraging distinct mechanisms to achieve long-term therapeutic efficacy